ChemoCentryx (CCXI) Peer Comparison
$12.10
$0.01
(0.08%)
As on 17-Sep-2026 14:33EDT
Market cap
$686 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
686 | 5,765 | 3,354 | 442 | 339 |
Revenue ($ Mln) |
-- | 440 | 2,883 | 330 | 58 |
Net Profit ($ Mln) |
-134.20 | -1,435.01 | -118.30 | 100.20 | -50.70 |
Net Margin (%) |
-- | -325.91 | -4.10 | 30.33 | -88.09 |
RoE (%) |
-40.17 | -- | -- | 30.44 | -54.90 |
Price to Earnings |
-- | -- | -- | 4.62 | -- |
Price-To-Book |
-- | -- | 1.35 | 1.29 | 2.29 |
Income Statement ($ Mln)
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
32.22 | 319.02 | 2,631.80 | 335.44 | 45.97 |
|
Cost of Revenue
|
0.30 | 281.12 | 1,584.40 | 46.04 | 53.38 |
|
Gross Profit
|
31.92 | 37.90 | 1,047.40 | 289.40 | -7.40 |
|
Operating Expenses
|
0.17 | 262.45 | 899.40 | 146.67 | 47.52 |
|
Operating Profit (EBIT)
|
-0.17 | -224.55 | 148.00 | 142.73 | -54.92 |
|
Other Income
|
0.86 | -- | 0.00 | -18.08 | 0.76 |
|
Profit before Tax
|
0.38 | -288.03 | -159.30 | 142.73 | -71.25 |
|
Provision for Tax
|
-- | 0.58 | 16.20 | 35.94 | 0.12 |
|
Profit after Tax (Net Income)
|
0.38 | -288.62 | -198.30 | 106.84 | -71.36 |
|
Minority Interest
|
-- | -- | -- | 19.55 | -- |
|
Consolidated Profit
|
-131.76 | 47.31 | -0.34 | -57.92 | 10.20 |
Liabilities ($ Mln)
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
399.79 | -962.74 | -1,276.40 | 317.57 | 38.16 |
|
Minority Interest
|
-- | -- | -- | 19.55 | -- |
|
Non-Current Liabilities
|
15.99 | 2,528.98 | 3,507.00 | 160.23 | 33.39 |
|
Current Liabilities
|
0.13 | 781.40 | 2,868.70 | 594.94 | 33.80 |
|
Total Liabilities
|
415.91 | 2,347.64 | 5,244.20 | 1,072.73 | 105.35 |
Assets ($ Mln)
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
414.85 | 1,452.11 | 3,924.70 | 349.32 | 26.39 |
|
Current Assets
|
1.06 | 895.54 | 1,319.50 | 723.41 | 78.96 |
|
Total Assets
|
415.91 | 2,347.64 | 5,244.20 | 1,072.73 | 105.35 |
|
Total Debt*
|
23.64 | 1,060.33 | 3,975.30 | 152.49 | 40.23 |
|
Net Current Assets
|
0.93 | 114.14 | -1,558.20 | -- | 46.32 |
Cashflow ($ Mln)
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.63 | 278.25 | 24.80 | 71.03 | -27.33 |
|
Cash Flow from Investing Activities
|
-414.00 | -740.75 | -12.20 | 0.62 | -2.72 |
|
Cash from Financing Activities
|
415.37 | -63.10 | 114.30 | -1.08 | 67.83 |
|
Net Cash Inflow / Outflow
|
17.68 | -- | 1.42 | -56.22 | 1.13 |
Ratios
Profitability Ratios
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-34.71 | -120.97 | -7.47 | 24.90 | -106.54 |
|
ROE (%)
|
-39.23 | 32.38 | 17.08 | 38.62 | -183.40 |
|
ROA (%)
|
-27.90 | -14.63 | -3.83 | 9.34 | -73.37 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-398.26 | -90.47 | -7.53 | 31.85 | -155.23 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.50 | -0.38 | -0.18 | 0.13 | 0.12 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-138.01 | 78.05 | -54.32 | 41.10 | -2.32 |
|
EPS Growth (%)
|
-1.24 | 0.80 | -0.54 | 0.40 | 0.92 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-19.34 | -19.80 | -13.35 | 5.90 | -4.10 |
|
Price / Book Value
|
8.91 | -5.94 | -2.07 | 1.99 | 7.67 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-17.58 | -31.10 | 5.65 | 2.71 | -4.37 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.08 | -1.10 | -3.11 | 0.48 | 1.05 |
|
Short term debt to equity ratio
|
0.07 | 0.37 | -1.08 | 0.00 | 0.22 |
|
Current Ratio
|
8.13 | 1.15 | 0.46 | 1.22 | 2.34 |
|
Quick Ratio
|
4.26 | -- | 0.54 | 7.13 | 1.53 |
|
Interest Coverage
|
-49.89 | -87.90 | 0.39 | 14.20 | 0.00 |
Operating Efficiency Ratios
| ChemoCentryx (CCXI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
1.28 | 105.69 | 29.34 | 61.95 | 18.06 |
|
Asset Turnover
|
0.07 | 0.16 | 0.51 | 0.29 | 0.47 |
|
Receivable days
|
3.29 | 193.60 | 125.70 | 281.90 | 49.75 |
|
Inventory Days
|
1,029.23 | -- | 0.00 | -1,955.46 | 263.57 |
|
Payable days
|
11,865.18 | 94.44 | 58.42 | 1,383.94 | 98.67 |
|
Cash Conversion Cycle
|
-10,832.66 | -- | 44.05 | -1,029.48 | 214.66 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
